Amarantus Bioscience Holdings Inc
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprieta… Read more
Amarantus Bioscience Holdings Inc (AMBS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2023: 0.000x
Based on the latest financial reports, Amarantus Bioscience Holdings Inc (AMBS) has a cash flow conversion efficiency ratio of 0.000x as of March 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($7.97K) by net assets ($-24.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Amarantus Bioscience Holdings Inc - Cash Flow Conversion Efficiency Trend (2008–2022)
This chart illustrates how Amarantus Bioscience Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Amarantus Bioscience Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amarantus Bioscience Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
U-Swirl Inc
PINK:SWRL
|
0.167x |
|
BARON OIL
BE:GHA
|
N/A |
|
Gold And Gemstone
PINK:GGSM
|
0.013x |
|
Golden Triangle Ventures Inc
PINK:GTVH
|
N/A |
|
KYN Capital Group Inc
PINK:KYNC
|
-0.360x |
|
Itokk Inc
PINK:IKTO
|
0.203x |
|
SPO Global Inc
PINK:SPOM
|
-0.168x |
|
Sentry Technology Corp
PINK:SKVY
|
0.004x |
Annual Cash Flow Conversion Efficiency for Amarantus Bioscience Holdings Inc (2008–2022)
The table below shows the annual cash flow conversion efficiency of Amarantus Bioscience Holdings Inc from 2008 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $-24.67 Million | $-4.50 Million | 0.182x | -63.38% |
| 2021-12-31 | $-19.93 Million | $-9.93 Million | 0.498x | +5615.51% |
| 2020-12-31 | $-9.48 Million | $-82.66K | 0.009x | +107.67% |
| 2019-12-31 | $-8.96 Million | $1.02 Million | -0.114x | -276.53% |
| 2018-12-31 | $-27.90 Million | $-1.80 Million | 0.064x | -40.43% |
| 2017-12-31 | $-18.02 Million | $-1.95 Million | 0.108x | -37.95% |
| 2016-12-31 | $-15.58 Million | $-2.71 Million | 0.174x | -90.56% |
| 2015-12-31 | $-8.69 Million | $-16.01 Million | 1.843x | -33.78% |
| 2014-12-31 | $-4.07 Million | $-11.33 Million | 2.783x | +502.56% |
| 2013-12-31 | $-7.52 Million | $-3.47 Million | 0.462x | +41.19% |
| 2012-12-31 | $-3.53 Million | $-1.15 Million | 0.327x | -61.08% |
| 2011-12-31 | $-3.35 Million | $-2.82 Million | 0.840x | +16031.77% |
| 2010-12-31 | $-74.86K | $-390.00 | 0.005x | -99.42% |
| 2009-12-31 | $-16.29K | $-14.59K | 0.895x | +101.12% |
| 2008-12-31 | $180.00 | $-14.36K | -79.789x | -- |